More News! 18 Feb 2019 Enormous Series A to Help Bring Epilepsy Drug to Market One of the biggest Series A rounds in European biotech, €159M ($180M), has been raised by the Swiss company Arvelle Therapeutics to help commercialize its epilepsy drug. Formed just this month, Arvelle plans to submit an application for EMA approval for the small molecule drug cenobamate, which it has licensed from the South Korean company […] February 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Feb 2019 10 European Genomics Companies to Watch Out For Next generation sequencing has revolutionized the biotech industry and genomics technology has changed dramatically over the last few years. There are many interesting European genomics companies, but here are 10 we thought especially worthy of mention. By 2025, the size of global genomics market is predicted to reach a whopping €24B, and unsurprisingly, there’s a […] February 18, 2019 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2019 Genetic Testing Improves Success of Kidney Transplants Genetic variations in cell surface proteins are able to predict kidney transplant success, shows Austrian research, serving as a potential screening tool for improving future transplants. Many kidney transplants fail over time because the patient’s immune system rejects the organ. This rejection happens because the immune system recognizes that particular proteins on the cell surface, such […] February 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 15 Feb 2019 This Lab-on-a-Chip Can Screen Millions of Bacteria in Parallel Our French biotech of the week, Biomillenia, is developing a lab-on-a-chip that can screen millions of strains of bacteria in a fraction of the time it takes for traditional methods. This technology can identify previously unculturable strains for use in agriculture, animal health, or microbiome-based therapies. Mission: To use lab-on-a-chip technology to culture and screen […] February 15, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 14 Feb 2019 London’s Biotech Ecosystem Boosted with €900M Expansion The British Library has greenlit the construction of a new research hub on its property in North London, increasing the business potential for the biotech ecosystem in the southeast of England. The new site, costing up to €900M (£800M), will expand premises held by the British Library, which is next to King’s Cross and the […] February 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2019 Hair Loss Biotech Ventures into Diabetes Market The Swedish biotech Follicum has added drugs for type 2 diabetes into its pipeline, which focuses on treatments for hair loss. The market for type 2 diabetes treatments is huge, and competitive. While many approved treatments help to control blood sugar in type 2 diabetes, fluctuating blood sugar levels can damage vital insulin-producing beta cells. Many diabetics […] February 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Inside Labiotech 14 Feb 2019 Say Hello to The Brand-New Labiotech.eu, Our Biggest Product Redesign Since We Launched 💥 You might have noticed that something changed on our site today. Indeed, we’re very proud to launch our brand-new website, which we started from scratch on a blank piece of paper. We are further improving your user experience and the page performance, and we’ll have the possibility of adding more crazy features in the coming […] February 14, 2019 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
Interview 13 Feb 2019 Embracing Risk to Succeed in Biotech Biotech can be a very risky business, but embracing the risk can be the key to success. At our last Labiotech Refresh in Heidelberg, we got to talk to Friedrich von Bohlen, scientist, entrepreneur and investor, about how he approaches risk and what he thinks about the future of biotech. Friedrich von Bohlen is the […] February 13, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2019 First Plant in the Works to Turn Dairy Byproducts Into Plastics The company Glanbia Ireland is planning to construct the first industrial biorefinery that transforms dairy waste products into lactic acid, a building block for biodegradable plastics. Supported by the EU project AgriChemWhey, Glanbia Ireland plans to scale up biorefinery technology that ferments dairy waste, like whey permeate, into lactic acid, using a group of bacteria […] February 13, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 12 Feb 2019 First Industrial Plant to Turn Waste into Chemicals Will Open in France The French company Afyren has received up to €60M to commercialize a technology that uses bacteria to produce industrial chemicals from recycled plant waste instead of fossil fuels. Afyren takes sugars from the waste byproducts of agriculture, food, and other industries, and ferments the sugars into industrial chemicals using bacteria. With this new funding, the […] February 12, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Inside Labiotech 12 Feb 2019 Why We Love Being the Main Media Partner of BIO-Europe We love partnering with cool people and companies—in return, we get to be in the middle of the action, get our name out there, and bring you all the very best of the events we attend. One of our favorite partnerships is with EBD Group, which are running BIO-Europe. Here’s why we love partnering with […] February 12, 2019 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 11 Feb 2019 Series A to Fund Therapy That Exposes Cancer to Immune System The UK biotech Grey Wolf Therapeutics has raised €11.4M (£10M) to fuel the development of a cancer therapy that flushes tumor cells out of hiding from the immune system. Many approved cancer immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have made a big difference for many people with cancer. However, a common problem with […] February 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email